Johnson & Johnson (JNJ)
Johnson & Johnson, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Johnson & Johnson is right in the middle: the good and the not-so-good roughly cancel out.
- What's working
- It carries less debt and has more breathing room than most other healthcare companies.
- Worth watching
- Its growth over the past year trails most other healthcare companies.
Analyst price target
~12-month · 22 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech…
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 138,200
- Headquarters
- New Brunswick, NJ
Similar stocks
What’s behind the score
Valuation
P/E 38.8 — lower than 39% of Healthcare peers
P/B 7.2 — lower than 29% of Healthcare peers
P/S 6.2 — lower than 33% of Healthcare peers
EV/EBITDA 18.9 — lower than 27% of Healthcare peers
EV/Revenue 6.5 — lower than 33% of Healthcare peers
PEG 2.8 — lower than 4% of Healthcare peers
Profitability & quality
Gross margin 67.8% — higher than 63% of Healthcare peers
Operating margin 25.1% — higher than 60% of Healthcare peers
Net margin 16.2% — higher than 70% of Healthcare peers
Financial health
Debt/equity 0.6 — lower than 63% of Healthcare peers
Cash/debt 0.42 — higher than 76% of Healthcare peers
Debt/EBITDA 1.44 — lower than 72% of Healthcare peers
Growth
Revenue growth 5.9% YoY — higher than 37% of Healthcare peers
Earnings growth -96.0% YoY — higher than 4% of Healthcare peers
Ownership & investor activity
Payout ratio 60.7% — somewhat unusual vs Healthcare peers
Net insider selling, -2.3% of insider shares
Institutions net sold, -13.0% of shares held
Insiders hold 0.1% of shares outstanding
1.0% of float sold short
Momentum
Mixed vs its moving averages
74% of the way from its 52-week low to high